ADMA · CIK 0001368514 · operating
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets plasma-derived biologics for immune deficiencies and infectious diseases. The company's primary products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies indicated for primary humoral immunodeficiency treatment, and Nabi-HB, a human polyclonal antibody product used for post-exposure prophylaxis following potential hepatitis B exposure. The company also maintains a pipeline of plasma-derived therapeutics in development.
The company operates through two main segments: ADMA BioManufacturing, which handles production of its specialty plasma biologics, and Plasma Collection Centers, which operate source plasma collection facilities. Products are distributed through independent distributors, drug wholesalers, specialty pharmacies, and alternate site providers in the United States and internationally.
ADMA Biologics employs approximately 640 full-time employees and maintains its headquarters in Ramsey, New Jersey. The company was incorporated in Delaware in 2004 and is listed on the Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.60 | $0.62 | -25.9% | |
| 2024 | $0.81 | $0.85 | +723.1% | |
| 2023 | $-0.13 | $-0.13 | +60.6% | |
| 2022 | $-0.33 | $-0.33 | +35.3% | |
| 2021 | $-0.51 | $-0.51 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-25 | 0001140361-26-006815 | SEC ↗ |
| 2024-12-31 | 2025-03-18 | 0001140361-25-009257 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001140361-24-010147 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0001140361-23-013467 | SEC ↗ |
| 2021-12-31 | 2022-03-24 | 0001140361-22-011030 | SEC ↗ |
| 2020-12-31 | 2021-03-25 | 0001193805-21-000411 | SEC ↗ |
| 2019-12-31 | 2020-03-13 | 0001193805-20-000348 | SEC ↗ |
| 2018-12-31 | 2019-03-13 | 0001193805-19-000281 | SEC ↗ |
| 2017-12-31 | 2018-03-29 | 0001193805-18-000470 | SEC ↗ |
| 2016-12-31 | 2017-02-24 | 0001193805-17-000330 | SEC ↗ |
| 2015-12-31 | 2016-03-23 | 0001193805-16-002889 | SEC ↗ |
| 2014-12-31 | 2015-03-09 | 0001193805-15-000352 | SEC ↗ |
| 2013-12-31 | 2014-03-28 | 0001193805-14-000641 | SEC ↗ |
| 2012-12-31 | 2013-03-06 | 0001193805-13-000585 | SEC ↗ |
| 2011-06-30 | 2011-09-27 | 0001144204-11-054936 | SEC ↗ |
| 2010-06-30 | 2010-09-23 | 0001144204-10-050666 | SEC ↗ |
| 2009-06-30 | 2009-09-24 | 0000930413-09-004889 | SEC ↗ |